La vendita allo scoperto per Bitwise Ethereum ETF Common shares of beneficial interest dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Bitwise Ethereum ETF Common shares of beneficial interest. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Bitwise Ethereum ETF Common shares of beneficial interest (ARCA:ETHW), Report sulle vendite allo scoperto

The Funds principal investment strategy is to invest directly in ether (ETH). The fund enables investors to gain exposure to the price movement of ether through a traditional investment vehicle while seeking to minimize administrative costs. The Funds ether is held with one of the worlds leading crypto asset custodians.

Bitwise Ethereum ETF

Bitwise Ethereum ETF Common shares of beneficial interest

EthereumPoW - United States Dollar

5 analysts have shared their evaluations of STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $33.4, a high estimate of $36.00, and a low estimate of $30.00. Experiencing a 12.11% decline, the current average is now lower than the previous average price target of $38.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732197625_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive STMicroelectronics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Anthony Stoss</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$35.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to STMicroelectronics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of STMicroelectronics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for STMicroelectronics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of STMicroelectronics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on STMicroelectronics analyst ratings.</a>
<h2>Get to Know STMicroelectronics Better</h2>
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
<h3>Unraveling the Financial Story of STMicroelectronics</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining STMicroelectronics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -26.63% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: STMicroelectronics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.8% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): STMicroelectronics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): STMicroelectronics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.37%, the company may face hurdles in achieving optimal financial performance.
Debt Management: STMicroelectronics's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For STMicroelectronics's Future

Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-22. Here's what investors need to know before the announcement.
Analysts estimate that Destination XL Group will report an earnings per share (EPS) of $0.03. 
The market awaits Destination XL Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 1.1% increase in the share price on the subsequent day.
Here's a look at Destination XL Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.04</td>
<td>0.06</td>
<td>0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.06</td>
<td>0.10</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>8.0%</td>
<td>2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732197623_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Destination XL Group were trading at $2.5 as of November 19. Over the last 52-week period, shares are down 37.66%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Destination XL Group</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Destination XL Group.
The consensus rating for Destination XL Group is Buy, derived from 1 analyst ratings. An average one-year price target of $4.0 implies a potential 60.0% upside.
<h3>Comparing Ratings with Competitors</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of ThredUp, Citi Trends and Tilly's, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, ThredUp is favoring an Outperform trajectory, with an average 1-year price target of $3.0, suggesting a potential 20.0% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Citi Trends, with an average 1-year price target of $17.0, implying a potential 580.0% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Tilly's, with an average 1-year price target of $6.0, suggesting a potential 140.0% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for ThredUp, Citi Trends and Tilly's are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Destination XL Group</td>
<td>Buy</td>
<td>-10.87%</td>
<td>$60.17M</td>
<td>1.53%</td>
</tr>
<tr>
<td>ThredUp</td>
<td>Outperform</td>
<td>-11.00%</td>
<td>$51.98M</td>
<td>-31.81%</td>
</tr>
<tr>
<td>Citi Trends</td>
<td>Buy</td>
<td>1.73%</td>
<td>$54.93M</td>
<td>-12.64%</td>
</tr>
<tr>
<td>Tilly's</td>
<td>Neutral</td>
<td>1.82%</td>
<td>$49.92M</td>
<td>-0.05%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Destination XL Group ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity.
<h3>About Destination XL Group</h3>
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets.
<h3>Destination XL Group's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Destination XL Group's revenue growth over 3 months faced difficulties. As of 31 July, 2024, the company experienced a decline of approximately -10.87%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Destination XL Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.53%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Destination XL Group's ROA stands out, surpassing industry averages. With an impressive ROA of 0.63%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Destination XL Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.13.
<a href="https://www.benzinga.com/quote/DXLG/earnings">To track all earnings releases for Destination XL Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

DXLG

Earnings Outlook For Destination XL Group

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 24.26% since its last report. The company recently reported that it has 888 thousand shares sold short, which is 1.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732197622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Molina Healthcare's Recent Short Interest

News

Mediaocean To Acquire Innovid For $3.15 Per Share In $500M Deal, Merging With Flashtalking To Create A Leading Independent Omnichannel Ad Tech Platform, Expected To Close In Early 2025

Discover Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) short percent of float has risen 12.72% since its last report. The company recently reported that it has 4.27 million shares sold short, which is 1.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.64 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Discover Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732197617_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Discover Finl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Discover Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Discover Finl's peer group average for short interest as a percentage of float is 7.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Discover Finl's Recent Short Interest

Global Blue Gr Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-22. Here's what investors need to know before the announcement.
Analysts estimate that Global Blue Gr Holding will report an earnings per share (EPS) of $0.03. 
Investors in Global Blue Gr Holding are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.06, leading to a 1.42% increase in the share price on the subsequent day.
Here's a look at Global Blue Gr Holding's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.07</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.02</td>
<td>0.01</td>
<td>0.06</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>14.000000000000002%</td>
</tr>
</tbody>
</table>

<h3>Market Performance of Global Blue Gr Holding's Stock</h3>
Shares of Global Blue Gr Holding were trading at $5.57 as of November 19. Over the last 52-week period, shares are up 24.89%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/GB/earnings">To track all earnings releases for Global Blue Gr Holding visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Global Blue Gr Holding

Providing a diverse range of perspectives from bullish to bearish, 29 analysts have published ratings on Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">11</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $126.83, along with a high estimate of $150.00 and a low estimate of $57.00. Observing a 10.56% increase, the current average has risen from the previous average price target of $114.72. 
<img src="https://www.benzinga.com/files/images/story/2024/1732197611_0_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Trade Desk. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Sell</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Vikram Kesavabhotla</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$142.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Dan Salmon</td>
<td>New Street Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Nathanson</td>
<td>MoffettNathanson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Reif Ehrlich</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$109.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Trade Desk. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Trade Desk compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Trade Desk's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Trade Desk's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TTD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Trade Desk analyst ratings.</a>
<h2>Delving into Trade Desk's Background</h2>
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.
<h3>Breaking Down Trade Desk's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Trade Desk's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 27.32%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.99%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Trade Desk's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.74% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.77%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Trade Desk Stands With Analysts

American Finl Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFG#NYSE">AFG</a>) short percent of float has fallen 10.14% since its last report. The company recently reported that it has 893 thousand shares sold short, which is 1.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.13 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>American Finl Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732197611_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for American Finl Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing American Finl Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, American Finl Gr's peer group average for short interest as a percentage of float is 1.74%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(AFG) - Analyzing American Finl Gr's Short Interest

NMHIW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

APLM

Apollomics shares are trading lower after the company announced a 1-for-100 reverse stock split.

Cantor Fitzgerald analyst Yi Fu Lee reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and maintains $445 price target.

Price Target

Reiteration

PANW

Cantor Fitzgerald Reiterates Overweight on Palo Alto Networks, Maintains $445 Price Target

The International Criminal Court on Thursday issued arrest warrants for Israeli Prime Minister Benjamin Netanyahu and former defense minister Yoav Gallant, "for crimes against humanity and war crimes" in the <a href="https://www.benzinga.com/markets/emerging-markets/24/11/41757546/israels-netanyahu-fires-defense-minister-gallant-over-lack-of-trust-in-war-management-oi">ongoing war in Gaza</a>.
Netanyahu and Gallant intentionally deprived civilians in Gaza of food, water and medicine and medical supplies, as well as fuel and electricity, and used starvation as a method of warfare, the International Criminal Court alleges. 
The arrest warrants also allege both men deprived civilians in Gaza of fundamental rights, including the rights to life and health, and intentionally directed attacks against the civilian population of Gaza. The ICC&#8217;s Pre-trial Chamber I also found Netanyahu and Gallant are responsible for other inhumane acts. 
Israeli President Isaac Herzog called the arrest warrants a &#8220;dark day for justice&#8221; in a post on X, adding that the warrants are a &#8220;mockery&#8221; of those who fight for justice and &#8220;ignore the plight of the 101 Israeli hostages held in brutal captivity by Hamas in Gaza.&#8221; 
Herzog concluded: &#8220;This cynical exploitation of the international legal institutions reminds us once again of the need for true moral clarity in the face of an Iranian empire of evil that seeks to destabilize our region and the world, and destroy the very institutions of the free world.&#8221;
The court&#8217;s 124 member states would be obligated to arrest Netanyahu and Gallant if they entered those states, the Financial Times <a href="https://www.ft.com/content/0b62f17a-97db-4817-90f8-f98adead79f0">said</a> in a report, adding that the ICC has no means of enforcing this. 
The Details: The court also issued a warrant for Hamas military leader Mohammed Deif. Israeli officials say Deif was killed in an airstrike in Gaza in July. Prosecutors said they issued the warrant because they were not able to confirm whether he is dead or alive. 
The ICC rejected Israel's challenge to the court's jurisdiction over "the situation in the State of Palestine" and over Israeli nationals.
Read Next: <a href="https://www.benzinga.com/24/11/42107863/us-futures-head-lower-as-nvidia-reports-slowdown-in-quarterly-revenue-growth-expert-says-market-weakness-is-perfectly-normal-but-late-november-is-still-possible">US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is &#8216;Perfectly Normal,&#8217; But Late November Rally Is Still Possible</a>
The ICC said in a press release that the arrest warrants are classified as secret, but the chamber decided to release the information since the conduct "appears to be ongoing." The chamber also said it considers it in the best interest of the victims to be aware of the issuance of the warrants. 
Other Developments:  U.S. envoy Amos Hochstein is in Israel for talks with Israeli officials over a cease-fire in Lebanon. Hochstein left Beirut on Wednesday after two days of meetings with Lebanese officials, <a href="https://www.washingtonpost.com/world/2024/11/21/israel-war-news-hamas-gaza-palestine/">according</a> to The Washington Post. 
The United States vetoed a U.N. Security Council resolution put forward Wednesday that called for a cease-fire in Gaza because it was not contingent on the release of hostages still held and it did not condemn Hamas.
At least 44,056 people have been killed in Gaza during the war and 104,268 injured, the Post reported, citing the Gaza Health Ministry. At least 3,558 people have been killed and 15,123 injured in Lebanon, the report said, citing Lebanon&#8217;s health ministry. The organizations do not distinguish between civilians and combatants. 
Israel estimates that approximately 1,200 people were killed in the Oct. 7, 2023 attack and says 377 soldiers have been killed in its military operation in Gaza.
Image: Shutterstock.

Politics

Legal

Global

International Criminal Court Issues Arrest Warrants For Israeli Prime Minister Netanyahu, Gallant For War Crimes

AGFY

Agrify shares are trading lower. The company announced a non-brokered private placement at $22.30 per share for approximately $25.9 million in proceeds.

Barclays analyst Lauren Lieberman maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Overweight and raises the price target from $74 to $79.

BRBR

Barclays Maintains Overweight on BellRing Brands, Raises Price Target to $79

VNET

VNET Group shares are trading higher after the company reported Q3 EPS and revenue that rose year-over-year.

Barclays analyst Brian Morton maintains Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) with a Overweight and raises the price target from C$126 to C$143.

TSX:BMO

Barclays Maintains Overweight on Bank of Montreal, Raises Price Target to C$143

On Wednesday, the FDA granted accelerated approval to Jazz Pharmaceuticals plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) <a href="https://www.benzinga.com/pressreleases/24/11/n42101689/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-a" target="_blank" rel="noreferrer noopener">biliary tract cancer (BTC)</a>.
Ziihera&nbsp;was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41338366/jazz-pharmaceuticals-zepzelcatecentriq-combo-regimen-can-potentially-delay-disease-progression-ex" rel="noreferrer noopener">Jazz Pharmaceuticals&#8217; Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer</a>
The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.
Regulatory reviews of zanidatamab for BTC remain ongoing in China and Europe.
In late 2022, Zymeworks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) entered into a license and collaboration agreement with Jazz Pharmaceuticals for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan, and all other territories except for those Asia Pacific territories previously <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42106981/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-tr" rel="noreferrer noopener">licensed by Zymeworks</a>.
Under the Jazz license and collaboration agreement terms, Zymeworks has earned a milestone payment of $25 million based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.
Zymeworks says the approval represents the first FDA-approved therapy in its pipeline and validates the company&#8217;s Azymetric bispecific platform technology.
Price Action: JAZZ stock closed at $119.24 on Wednesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease" target="_blank" rel="noreferrer noopener">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

JAZZ

ZYME

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

Universal Technical Institute shares are trading higher after the company reported better-than-expected Q4 EPS and sales, and provided FY2024 revenue guidance above analyst estimates.

AppLovin shares are trading higher after the company priced a public offering of $3.55 billion in senior notes.

In Anaheim at the recent <a href="https://cannabismarketspotlight.com/california/anaheim-november-12/">Cannabis Market Spotlight: California </a>event, seasoned cannabis entrepreneur Seth Yakatan shared his perspective on the cannabis industry's current landscape and future potential. 
Despite recent shifts in cannabis stock prices, Yakatan believes the sector remains fundamentally stable. "The technical fundamentals of the sector pretty much remained the same," he noted, adding that he saw the price drop as an opportunity and "just bought more stocks cheaper."
<h4 class="wp-block-heading">Federal Policy and a Cautious Outlook</h4>
Looking ahead, Yakatan discussed the impact of upcoming federal decisions on the cannabis industry. He remains "cautiously optimistic" but believes it could be March before any clear direction emerges. 
Yakatan highlighted three key areas to watch: the selection of a new Attorney General, possibly reclassifying cannabis to Schedule III and ongoing legislative changes in states like Pennsylvania. "Anything other than that's probably just speculation," he remarked, stressing that the path forward depends on these developments.
<h4 class="wp-block-heading">California's Market Leads the Way</h4>
Yakatan also expressed confidence in California's enduring position as a leader in the U.S. cannabis market, calling it "still the biggest cannabis market in the United States." 
Although he acknowledged challenges within California's market, he emphasized the dedication of long-standing businesses that continue to secure investment and make strides in the industry. "I don't see that dynamic changing," Yakatan stated, underscoring his confidence in California's cannabis market to continue thriving.
Yakatan's observations at the event reflected the optimism shared by many industry experts, signaling a resilient future for cannabis even as it faces a complex regulatory environment.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111313/exclusive-fluent-launches-new-cannabis-concentrates-line-for-medical-marijuana-patients-in-florida">FLUENT Launches New Cannabis Concentrates Line For Medical Marijuana Patients In Florida</a></li>
</ul>
Image: AI-Generated Image

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

California's Cannabis Future: Why One Expert Believes The Market Will Hold Strong

Multi-Asset Solutions: Macro July 2024 Update

BlackRock's ETHA leads the pack as first ether ETF to hit $1B in net inflows

Cryptocurrencies: Bitcoin Inches Down To $59K

Monthly Market Recap: Fed Soothes With Future Rate Cuts

Prepare For Election Outcomes: Views From Our Portfolio Managers

Will Fed's easing cycle reverse the tide of ether ETF outflows? Analyst weighs in

Bitwise submits S-1 registration for XRP ETF launch

3 Roadblocks To Crypto Adoption

Cryptocurrencies: Bitcoin Climbs Above $60K

Optimal Crypto Allocation For Portfolios

AAAU

AEMB

ANGL

AQWA

ARKB

AVEM

AVES

AVMU

AYTEF

BATT

BCHG

BGLD

BITB

BITO

BMVP

BRRR

BSMO

BSMP

BSMQ

BSMR

BSMS

BSMT

BTCO

BTCW

CBON

CEMB

CETH

CLOI

COPX

CPER

DBEM

DEFI

DEUS

DFEV

DIEM

EBLU

EBND

EFIX

EJUL

EMBD

EMCB

EMCR

EMHC

EMHY

EMLC

EMTL

EMXC

EQAL

ESGE

ETHA

ETHE

ETHV

ETHW

EZBC

EZET

FAIL

FALN

FBTC

FCAL

FDMO

FEMB

FETH

FLMB

FLMI

FLQM

FMAT

FMNY

FRDM

FSCS

FSMB

FTAG

FTDS

FTRI

FUMB

GBTC

GDMN

GDXD

GDXJ

GDXU

GLDI

GLDM

GLTR

GOAU

GOEX

GOVZ

GRPM

GUNR

GURU

HEEM

HMOP

HODL

HYDR

HYEM

IAUM

IBIT

IBMM

IBMN

IBMO

IBMP

IBMQ

IEMG

IGLD

ILCG

IMCB

INDA

INDL

INDY

INMU

IUSG

IVOO

JAAA

JBBB

JEMA

JEMTF

JHMM

JJCTF

JJETF

JJMTF

JJNTF

JJTFF

Comments

Bitwise Ethereum ETF Common shares of beneficial interest

Vendite allo scoperto

Bitwise Ethereum ETF Common shares of beneficial interest (ARCA:ETHW), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO